TrialPloS one2021

Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.

Jaejoon Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.